Bio Rad Laboratories Inc (NYSE:BIO)
| 460.57 Delayed Data As of Mar 24 |  +4.25 / +0.93%Today’s Change | 344.63 Today|||52-Week Range 607.54 | +9.53% Year-to-Date |
Latest BIO News | Press Releases
| Select Medical's (SEM) Orlando Facility to Boost Post-Acute Care Mar 21 / Zacks.com - Paid Partner Content | Here's Why You Should Retain Acadia (ACHC) in Your Portfolio Mar 15 / Zacks.com - Paid Partner Content |
| SurModics (SRDX) Moves 5.4% Higher: Will This Strength Last? Mar 17 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 456.32 |
| Today’s open | 452.75 |
| Day’s range | 448.56 - 460.90 |
| Volume | 138,433 |
| Average volume (3 months) | 174,742 |
| Market cap | $12.0B |
Data as of 3:59pm ET, 03/24/2023
Growth & Valuation
| Earnings growth (last year) | -185.57% |
| Earnings growth (this year) | +8.65% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -4.12% |
| P/E ratio | NM |
| Price/Sales | 4.47 |
| Price/Book | 1.50 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BRKRBruker Corp | +0.96 | +1.28% |
| QGENQiagen NV | +0.31 | +0.68% |
| PKIPerkinElmer Inc | +2.48 | +1.98% |
| WATWaters Corp | +1.92 | +0.64% |
Data as of 4:00pm ET, 03/24/2023
Financials
| Next reporting date | April 27, 2023 |
| EPS forecast (this quarter) | $3.80 |
| Annual revenue (last year) | $2.8B |
| Annual profit (last year) | -$3.6B |
| Net profit margin | -129.45% |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Hercules, California |
Forecasts
